Uncategorized
Ocular Therapeutix reports positive results from phase 3a trial of OTX-DP
Ocular Therapeutix announced positive top-line clinical results from a phase 3a trial on the safety and efficacy of OTX-DP for the treatment of ocular inflammation and pain after cataract surgery. The trial enrolled 247 patients who were treated with OTX-DP (sustained-release dexamethasone); 33.7% of patients showed an absence of inflammatory cells in the anterior chamber on day 14 compared with 14.6% of patients who were treated with a placebo vehicle control punctum plug (P = .0015). Seventy-six percent of treated patients reported absence of pain in the study eye on (Read more...)